SAN FRANCISCO, May 22, 2023 (GLOBE NEWSWIRE) — Hagens Berman urges Chinook Therapeutics, Inc. (NASDAQ: KDNY) investors who suffered substantial losses to submit your losses now. The investigation focuses on Chinook’s statements related to the commercial prospects for its lead product candidate (atrasentan), which is under development, to treat patients…Read More
KDNY INVESTIGATION Hagens Berman National Trial Attorneys Encourages Chinook Therapeutics KDNY Investors with Substantial Losses to Contact Firms Attorneys Firm Investigating Possible Securities Law Violations
